UNIVERSITY OF UTAH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1850-02-28

Employees: 10K

Market Cap: -

Website: http://www.utah.edu

Clinical Trials

The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Drug: phenylephrine

First Posted Date: 2008-01-03

Last Posted Date: 2012-06-13

Lead Sponsor: University of Utah

Target Recruit Count: 15

Registration Number: NCT00585091

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

Phase 4

Completed

Conditions: Obesity
Venous Thrombosis
Anticoagulants

Interventions: Drug: Enoxaparin 0.5 mg/kg once daily

First Posted Date: 2008-01-03

Last Posted Date: 2018-04-05

Lead Sponsor: University of Utah

Target Recruit Count: 28

Registration Number: NCT00585182

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

CRT Pilot Study for Children With Heart Failure

Completed

Conditions: Chronic Pediatric Heart Failure

Interventions: Device: CRT device implant

First Posted Date: 2008-01-03

Last Posted Date: 2023-05-11

Lead Sponsor: University of Utah

Target Recruit Count: 7

Registration Number: NCT00585065

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Effects of Vitamin D on Renin Expression in Hypertensive Patients

Early Phase 1

Terminated

Conditions: Hypertension
Vitamin D Deficiency

Interventions: Drug: calcitriol
Drug: Placebo

First Posted Date: 2008-01-03

Last Posted Date: 2016-05-27

Lead Sponsor: University of Utah

Target Recruit Count: 12

Registration Number: NCT00585442

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Phase 2

Terminated

Conditions: Solid Tumors
Cancer Brain
Gastrointestinal Stromal Tumors

Interventions: Drug: Peginterferon-alpha 2b (PegIFNa2b);
Drug: Imatinib

First Posted Date: 2008-01-03

Last Posted Date: 2017-02-10

Lead Sponsor: University of Utah

Target Recruit Count: 8

Registration Number: NCT00585221

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Bevacizumab and Erlotinib

First Posted Date: 2008-01-03

Last Posted Date: 2015-09-24

Lead Sponsor: University of Utah

Target Recruit Count: 50

Registration Number: NCT00585377

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

The Effects of Celecoxib on Bone Ingrowth

Early Phase 1

Terminated

Conditions: Bone Ingrowth
Pain

Interventions: Drug: Celecoxib

First Posted Date: 2008-01-03

Last Posted Date: 2016-03-14

Lead Sponsor: University of Utah

Target Recruit Count: 9

Registration Number: NCT00585156

Locations: 🇺🇸
Veteran Affairs (VA) Medical Center, Salt Lake City, Utah, United States

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Myfortic

First Posted Date: 2008-01-03

Last Posted Date: 2016-05-06

Lead Sponsor: University of Utah

Target Recruit Count: 21

Registration Number: NCT00585468

Locations: 🇺🇸
Univ of Utah-Solid Organ Transplant, Salt Lake City, Utah, United States

Tools for the Objective Clinical Assessment of Pediatric Spinal Deformity

Withdrawn

Conditions: Thoracic Insufficiency Syndrome
TIS

Interventions: Other: Digital Photography

First Posted Date: 2008-01-03

Last Posted Date: 2024-01-09

Lead Sponsor: University of Utah

Registration Number: NCT00585234

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease

Completed

Conditions: End Stage Renal Disease

First Posted Date: 2007-12-03

Last Posted Date: 2016-08-11

Lead Sponsor: University of Utah

Target Recruit Count: 145

Registration Number: NCT00566670

Locations: 🇺🇸
Vanderbilt University Medical Centet, Nashville, Tennessee, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy